Erythroid Di ff erentiation Regulator 1 Ameliorates Collagen-Induced Arthritis via Activation of Regulatory T Cells

: Erythroid di ff erentiation regulator 1 (Erdr1) has been identified as an anti-inflammatory factor in several disease models, including collagen-induced arthritis (CIA), but its exact mechanisms are still not fully understood. Here, the involvement of regulatory T (Treg) cells in Erdr1-improved CIA was investigated. In the CIA model, Erdr1 was confirmed to reduce collagen-specific IgM in plasma and plasma cells in draining lymph nodes. Importantly, the downregulated Treg cell ratio in draining lymph nodes from CIA mice was recovered by Erdr1 treatment. In addition, administration of Erdr1 improved the CIA score and joint tissue damage, while it revealed no e ff ect in Treg cell-depleted CIA mice, indicating that Treg cells mediate the therapeutic e ff ects of Erdr1 in the CIA model. Results from in vitro experiments also demonstrated that Erdr1 significantly induced Treg cell di ff erentiation and the expression of Treg activation markers, including CD25, CD69, and CTLA4 in CD4 + Foxp3 + cells. Furthermore, Erdr1-activated Treg cells dramatically suppressed the proliferation of responder T cells, suggesting that they are functionally active. Taken together, these results show that Erdr1 induces activation of Treg cells and ameliorates rheumatoid arthritis via Treg cells.

[1]  E. Proietti,et al.  Type I interferons induce peripheral T regulatory cell differentiation under tolerogenic conditions. , 2020, International immunology.

[2]  Su-Jin Jung,et al.  Erythroid differentiation regulator 1 strengthens TCR signaling in thymocytes by modulating calcium flux. , 2019, Cellular immunology.

[3]  D. Hafler,et al.  Regulatory T cells in autoimmune disease , 2018, Nature Immunology.

[4]  U. Kalinke,et al.  Regulatory T-Cells Mediate IFN-α-Induced Resistance against Antigen-Induced Arthritis , 2018, Front. Immunol..

[5]  Yan Kang,et al.  Tregs: Where We Are and What Comes Next? , 2017, Front. Immunol..

[6]  N. Kopitar-Jerala The Role of Interferons in Inflammation and Inflammasome Activation , 2017, Front. Immunol..

[7]  R. Holmdahl,et al.  CTLA‐4 expressed by FOXP3+ regulatory T cells prevents inflammatory tissue attack and not T‐cell priming in arthritis , 2017, Immunology.

[8]  Ryan M. O’Connell,et al.  Microbiota promotes systemic T-cell survival through suppression of an apoptotic factor , 2017, Proceedings of the National Academy of Sciences.

[9]  Seung Beom Park,et al.  Therapeutic effect of erythroid differentiation regulator 1 (Erdr1) on collagen-induced arthritis in DBA/1J mouse , 2016, Oncotarget.

[10]  Y. Shima,et al.  The Proportion of Regulatory T Cells in Patients with Rheumatoid Arthritis: A Meta-Analysis , 2016, PloS one.

[11]  G. Plitas,et al.  Regulatory T Cells: Differentiation and Function , 2016, Cancer Immunology Research.

[12]  Haoming Zhou,et al.  CD25 signaling regulates the function and stability of peripheral Foxp3+ regulatory T cells derived from the spleen and lymph nodes of mice. , 2016, Molecular immunology.

[13]  D. Cho,et al.  Downregulation of erythroid differentiation regulator 1 (Erdr1) plays a critical role in psoriasis pathogenesis , 2016, Experimental dermatology.

[14]  A. Moore,et al.  Expanding antigen-specific regulatory networks to treat autoimmunity , 2016, Nature.

[15]  A. Izcue,et al.  Higher Sensitivity of Foxp3+ Treg Compared to Foxp3- Conventional T Cells to TCR-Independent Signals for CD69 Induction , 2015, PloS one.

[16]  박현정,et al.  Recombinant erythroid differentiation regulator 1 inhibits both inflammation and angiogenesis in a mouse model of rosacea , 2015 .

[17]  M. Toribio,et al.  Maintenance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expression. , 2014, Journal of autoimmunity.

[18]  R. Cardiff,et al.  Manual hematoxylin and eosin staining of mouse tissue sections. , 2014, Cold Spring Harbor protocols.

[19]  D. Pardoll,et al.  Treg functional stability and its responsiveness to the microenvironment , 2014, Immunological reviews.

[20]  W. Lee,et al.  Recombinant Erdr1 suppresses the migration and invasion ability of human gastric cancer cells, SNU-216, through the JNK pathway. , 2013, Immunology letters.

[21]  W. Lee,et al.  Erythroid differentiation regulator 1, an interleukin 18-regulated gene, acts as a metastasis suppressor in melanoma. , 2011, The Journal of investigative dermatology.

[22]  Bin Li,et al.  FOXP3 and RORγt: transcriptional regulation of Treg and Th17. , 2011, International immunopharmacology.

[23]  A. Rudensky,et al.  Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. , 2011, Immunity.

[24]  M. Ehrenstein,et al.  Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis , 2008, Proceedings of the National Academy of Sciences.

[25]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[26]  E. Kelly,et al.  IL-2 and related cytokines can promote T cell survival by activating AKT , 2007, The Journal of Immunology.

[27]  S. Sakaguchi,et al.  Regulatory T cells – a brief history and perspective , 2007, European journal of immunology.

[28]  C. Akdis,et al.  Regulation of T cells and cytokines by the interleukin‐10 (IL‐10)‐family cytokines IL‐19, IL‐20, IL‐22, IL‐24 andIL‐26 , 2006, European journal of immunology.

[29]  F. Sánchez‐Madrid,et al.  CD69 is an immunoregulatory molecule induced following activation. , 2005, Trends in immunology.

[30]  W. Möller,et al.  EDR is a stress-related survival factor from stroma and other tissues acting on early haematopoietic progenitors (E-Mix). , 2004, Cytokine.

[31]  Johan Garssen,et al.  Transforming growth factor-beta inhibits human antigen-specific CD4+ T cell proliferation without modulating the cytokine response. , 2003, International immunology.

[32]  J. Dayer,et al.  Interleukin-18, rheumatoid arthritis, and tissue destruction. , 1999, The Journal of clinical investigation.

[33]  I. McInnes,et al.  A proinflammatory role for IL-18 in rheumatoid arthritis. , 1999, The Journal of clinical investigation.